Oneiro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.11 M
as on 16-11-2024
- Paid Up Capital ₹ 0.11 M
as on 16-11-2024
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 6.28%
(FY 2023)
- Ebitda
- Net Worth -2.84%
(FY 2023)
- Total Assets -0.85%
(FY 2023)
About Oneiro Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.11 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Gautam Arora and Divya Arora serve as directors at the Company.
- CIN/LLPIN
U51397UP2004PTC028871
- Company No.
028871
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Allahabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Oneiro Pharmaceuticals Private Limited offer?
Oneiro Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Multivitamin Tablets & Capsules, Calcium Tablet, Aceclofenac Tablet, Aceclofenac Paracetamol Tablet.
Who are the key members and board of directors at Oneiro Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gautam Arora  | Managing Director | 19-Jul-2004 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Divya Arora | Director | 02-Jun-2017 | Current |
Financial Performance of Oneiro Pharmaceuticals.
Oneiro Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 6.28% increase in profit. The company's net worth dipped by a decrease of 2.84%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Oneiro Pharmaceuticals?
In 2023, Oneiro Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oneiro Pharmaceuticals?
Unlock and access historical data on people associated with Oneiro Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oneiro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oneiro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
